The Effect of Vitamin D3 and Ketoconazole Combination on VDR-mediated P-gp Expression and Function in Human Colon Adenocarcinoma Cells: Implications in Drug Disposition and Resistance
- 18 May 2011
- journal article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 109 (2) , 97-102
Abstract
The vitamin D3 metabolite 1,25-dihydroxycholecalciferol (DHC) and analogues derived from it are being investigated as potential agents for the treatment of cancer. Combining ketoconazole (KTZ) with DHC has been recommended to enhance the anticancer activity of DHC. DHC exerts its biological activities through the vitamin D receptor (VDR). VDR is recognized to be a regulator of P-glycoprotein (P-gp), a member of the ABC transporter family well known for its role in multidrug resistance in cancer chemotherapy. We have investigated the effect of DHC and adding KTZ together with DHC on P-gp and VDR expression and the functional consequences of P-gp induction in intestinal human colonic adenocarcinoma cells LS174T cells. DHC increased P-gp expression by two times, and the addition of KTZ further increased the expression to four times. The combination of DHC + KTZ also significantly increased VDR expression, consistent with the enhanced increase in P-gp expression by this combination. The increase in P-gp expression was accompanied by increased P-gp function, as measured by decreased Rh123 accumulation in the LS174T cells. In addition, DHC significantly decreased colchicine cytotoxicity in a dose-sensitive manner, and the addition of KTZ further decreased the colchicine cytotoxicity, indicating the chemo-protective effect of DHC is enhanced by KTZ, consistent with the enhanced expression of P-gp. The results of this study raise the possibility that DHC and the addition of KTZ to DHC treatment may decrease the effectiveness of cancer chemotherapy by promoting P-gp-mediated drug resistance.Keywords
This publication has 36 references indexed in Scilit:
- Synthesis and CYP24A1 inhibitory activity of (E)-2-(2-substituted benzylidene)- and 2-(2-substituted benzyl)-6-methoxy-tetralonesEuropean Journal of Medicinal Chemistry, 2010
- CYP24A1 Inhibition Enhances the Antitumor Activity of CalcitriolEndocrinology, 2010
- 1α,25‐dihydroxyvitamin D3triggered vitamin D receptor and farnesoid X receptor‐like effects in rat intestine and liverin vivoBiopharmaceutics & Drug Disposition, 2009
- Involvement of Vitamin D Receptor in the Intestinal Induction of Human ABCB1Drug Metabolism and Disposition, 2009
- Up-Regulation of Transporters and Enzymes by the Vitamin D Receptor Ligands, 1α,25-Dihydroxyvitamin D3 and Vitamin D Analogs, in the Caco-2 Cell MonolayerThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Plasma 25-Hydroxyvitamin D Levels and Risk of Incident HypertensionHypertension, 2007
- Serum 25-Hydroxyvitamin D Levels and Risk of Multiple SclerosisJAMA, 2006
- Role of P-Glycoprotein in PharmacokineticsClinical Pharmacokinetics, 2003
- Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by RifampinJournal of Biological Chemistry, 2001
- Recent developments in the use of vitamin D analoguesExpert Opinion on Investigational Drugs, 2000